Japan Digestive Disease Week 2022
Strategic International Session3 (JSH)
October 27, 9:00–12:00, Room 9 (Fukuoka International Congress Center 413+414)
ST3-1_H
Epidemiology of hepatitis C virus: road to elimination
- Department of Epidemiology, Infectious Disease Control and Prevention, Hiroshima University
Hepatitis C virus (HCV) was first cloned in the world in 1989 and it is facilitated the development of diagnostic measures and treatments. In particular, since 2012, the therapeutic strategy against HCV has dramatically changed with the development of direct acting antivirals (DAA), which has an extremely high SVR rate. Currently, HCV became a controllable disease.
At the World Health Organization (2016), it announced its commitment to eradicate viral hepatitis by 2030 and unanimously adopted a global viral hepatitis eradication strategy.
The strategy sets the numerical target of eradicating hepatitis B and C by 2030, which contains 90% reduction in new infections, 65% reduction in annual mortality, 90% or more in diagnoses, and 80% or more in treatments.
Furthermore, in 2021, in addition to the relative targets so far, as absolute values, HBsAg positive rate of 5 years or younger is 0.1% or less, HBV mother-to-child transmission rate is 2% or less, and 4.0/100,000 or less in annual mortality rate due to HBV.
As for HCV, The HCV new infection rate is 5.0/100,000 or less (2.0/100 or less for PWID), and the annual mortality rate due to HCV is 2.0/100,000 or less.
In world, the number of people who persistent infected with HCV are estimated decrease: 130-170 million in 2002, 71 million in 2015 and 58 million in 2019.
In Japan, it was reported that 1.7-2.2 million were persistently infected with HCV in 2000. And then, the results of large-scale epidemiological research conducted by the Hepatitis Epidemiology Research Group of MHLW including analysis of National database, it decreased from 1.69-2.19 million in 2000, 0.98-1.58 million in 2011, and 0.88-1.3 million in 2015, and if the current situation continues, It is expected to decrease to 0.21-0.48 million in 2030.
However, in order to achieve this expectation, it is essential to raise the number of testing and promote the link to treatment based on the Hepatitis countermeasures according to local conditions.
In this presentation, some result from various epidemiological study in HCV will be shown.
At the World Health Organization (2016), it announced its commitment to eradicate viral hepatitis by 2030 and unanimously adopted a global viral hepatitis eradication strategy.
The strategy sets the numerical target of eradicating hepatitis B and C by 2030, which contains 90% reduction in new infections, 65% reduction in annual mortality, 90% or more in diagnoses, and 80% or more in treatments.
Furthermore, in 2021, in addition to the relative targets so far, as absolute values, HBsAg positive rate of 5 years or younger is 0.1% or less, HBV mother-to-child transmission rate is 2% or less, and 4.0/100,000 or less in annual mortality rate due to HBV.
As for HCV, The HCV new infection rate is 5.0/100,000 or less (2.0/100 or less for PWID), and the annual mortality rate due to HCV is 2.0/100,000 or less.
In world, the number of people who persistent infected with HCV are estimated decrease: 130-170 million in 2002, 71 million in 2015 and 58 million in 2019.
In Japan, it was reported that 1.7-2.2 million were persistently infected with HCV in 2000. And then, the results of large-scale epidemiological research conducted by the Hepatitis Epidemiology Research Group of MHLW including analysis of National database, it decreased from 1.69-2.19 million in 2000, 0.98-1.58 million in 2011, and 0.88-1.3 million in 2015, and if the current situation continues, It is expected to decrease to 0.21-0.48 million in 2030.
However, in order to achieve this expectation, it is essential to raise the number of testing and promote the link to treatment based on the Hepatitis countermeasures according to local conditions.
In this presentation, some result from various epidemiological study in HCV will be shown.